Benzinga's Top Downgrades

Analysts at Piper Jaffray downgraded MAKO Surgical

from “overweight” to “neutral.” The target price for MAKO Surgical has been raised from $26 to $30. MAKO Surgical's shares closed at $29.70 yesterday. Analysts at Barclays downgraded ARIAD Pharmaceuticals

from “overweight” to “underweight.” The target price for ARIAD Pharmaceuticals has been lowered from $25 to $4. ARIAD Pharmaceuticals' shares closed at $5.83 yesterday. Nomura downgraded Maxim Integrated Products

from “buy” to “neutral.” The target price for Maxim Integrated Products is set to $28. Maxim Integrated's shares closed at $29.22 yesterday. Analysts at Ascendiant Capital downgraded Leapfrog Enterprises

from “buy” to “neutral.” The target price for Leapfrog Enterprises has been lowered from $12 to $8. Leapfrog's shares closed at $9.15 yesterday.